Limits...
Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus

MSC NGs can specifically target tumor. (a) Representative Cryo-TEM images (n > 3) of hMSC-NGs (b) Binding of NGs (white arrows) to PC3 cells (NGs, red (DiI); cell, green (GFP); nucleolus, blue (DAPI)) evaluated using confocal microscopy. (c) In vivo prostate tumor targeting, and biodistribution of hMSC-NGs. Harvested tumors were dissociated into single cells and analyzed by flow cytometry for human CD90 as an indicator of NG fusion. Positive expression is calculated in the designated markers normalized to the untreated control group (black curves) based on the test events following ip (blue curves) or iv (purple curves) administration. Reproduced with permission26. Copyright 2014, ACS.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4440443&req=5

Figure 7: MSC NGs can specifically target tumor. (a) Representative Cryo-TEM images (n > 3) of hMSC-NGs (b) Binding of NGs (white arrows) to PC3 cells (NGs, red (DiI); cell, green (GFP); nucleolus, blue (DAPI)) evaluated using confocal microscopy. (c) In vivo prostate tumor targeting, and biodistribution of hMSC-NGs. Harvested tumors were dissociated into single cells and analyzed by flow cytometry for human CD90 as an indicator of NG fusion. Positive expression is calculated in the designated markers normalized to the untreated control group (black curves) based on the test events following ip (blue curves) or iv (purple curves) administration. Reproduced with permission26. Copyright 2014, ACS.

Mentions: MSCs containing therapeutic cargos could treat the diseases efficiently, but the missing cells might cause some adverse effects and even genetic risks. To overcome these shortcomings, a recent work attempted to remove the nucleic matter and homogenize the cells to form MSC NGs (Figure 7)26.


Cell or cell membrane-based drug delivery systems.

Tan S, Wu T, Zhang D, Zhang Z - Theranostics (2015)

MSC NGs can specifically target tumor. (a) Representative Cryo-TEM images (n > 3) of hMSC-NGs (b) Binding of NGs (white arrows) to PC3 cells (NGs, red (DiI); cell, green (GFP); nucleolus, blue (DAPI)) evaluated using confocal microscopy. (c) In vivo prostate tumor targeting, and biodistribution of hMSC-NGs. Harvested tumors were dissociated into single cells and analyzed by flow cytometry for human CD90 as an indicator of NG fusion. Positive expression is calculated in the designated markers normalized to the untreated control group (black curves) based on the test events following ip (blue curves) or iv (purple curves) administration. Reproduced with permission26. Copyright 2014, ACS.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4440443&req=5

Figure 7: MSC NGs can specifically target tumor. (a) Representative Cryo-TEM images (n > 3) of hMSC-NGs (b) Binding of NGs (white arrows) to PC3 cells (NGs, red (DiI); cell, green (GFP); nucleolus, blue (DAPI)) evaluated using confocal microscopy. (c) In vivo prostate tumor targeting, and biodistribution of hMSC-NGs. Harvested tumors were dissociated into single cells and analyzed by flow cytometry for human CD90 as an indicator of NG fusion. Positive expression is calculated in the designated markers normalized to the untreated control group (black curves) based on the test events following ip (blue curves) or iv (purple curves) administration. Reproduced with permission26. Copyright 2014, ACS.
Mentions: MSCs containing therapeutic cargos could treat the diseases efficiently, but the missing cells might cause some adverse effects and even genetic risks. To overcome these shortcomings, a recent work attempted to remove the nucleic matter and homogenize the cells to form MSC NGs (Figure 7)26.

Bottom Line: Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS.In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles.We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

View Article: PubMed Central - PubMed

Affiliation: 1. Tongji School of Pharmacy; ; 2. National Engineering Research Center for Nanomedicine; ; 3. Hubei Engineering Research Center for Novel DDS, Huazhong University of Science and Technology, Wuhan 430030, P R China.

ABSTRACT
Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

No MeSH data available.


Related in: MedlinePlus